Pim kinase inhibitors: a survey of the patent literature
- PMID: 20100002
- DOI: 10.1517/13543770903496442
Pim kinase inhibitors: a survey of the patent literature
Abstract
Importance of the field: Pim kinases have recently emerged as targets of interest in oncology and immune regulation. Ongoing studies have identified a role for these proteins in cell survival and proliferation, both functionally and mechanistically, and overexpression has been observed in a number of human cancers and inflammatory states.
Areas covered in this review: This report reviews the patent literature for Pim kinase inhibitors identified from a search of the Thomson patent databases from 1970 through July 2009. Full analyses are provided for publications reporting Pim kinases as primary targets, and a cursory description is given for those disclosing Pim as one of a limited number of secondary targets.
What the reader will gain: Readers will gain an overview of the various inhibitor series including coverage, potency, selectivity, protein binding features and therapeutic focus, and an appreciation for which scaffolds and structural features have been most highly exploited.
Take home message: A greater understanding of pathological mechanisms for Pim kinases has stimulated the recent development of a variety of inhibitor classes with one compound advancing into the clinic earlier this year. Ongoing studies will help define applications for these inhibitors in the treatment of Pim-associated human diseases.
Similar articles
-
Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.Expert Opin Ther Pat. 2014 Jan;24(1):5-17. doi: 10.1517/13543776.2014.848196. Epub 2013 Oct 17. Expert Opin Ther Pat. 2014. PMID: 24131033 Review.
-
The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms.Drug Resist Updat. 2011 Aug-Oct;14(4-5):203-11. doi: 10.1016/j.drup.2011.04.002. Epub 2011 May 20. Drug Resist Updat. 2011. PMID: 21601509 Review.
-
Cyclin-dependent kinase inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2010 Mar;20(3):377-404. doi: 10.1517/13543770903524284. Expert Opin Ther Pat. 2010. PMID: 20180621 Review.
-
Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review).Mol Med Rep. 2014 Jun;9(6):2051-60. doi: 10.3892/mmr.2014.2139. Epub 2014 Apr 11. Mol Med Rep. 2014. PMID: 24737044 Review.
-
Small molecule c-Met kinase inhibitors: a review of recent patents.Expert Opin Ther Pat. 2010 Feb;20(2):159-77. doi: 10.1517/13543770903514137. Expert Opin Ther Pat. 2010. PMID: 20100000 Review.
Cited by
-
RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition.Clin Cancer Res. 2014 Jun 15;20(12):3211-21. doi: 10.1158/1078-0432.CCR-13-3116. Epub 2014 Apr 25. Clin Cancer Res. 2014. PMID: 24771642 Free PMC article.
-
PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.Br J Cancer. 2012 Jul 24;107(3):491-500. doi: 10.1038/bjc.2012.272. Epub 2012 Jun 21. Br J Cancer. 2012. PMID: 22722314 Free PMC article.
-
Pharmacology of Modulators of Alternative Splicing.Pharmacol Rev. 2017 Jan;69(1):63-79. doi: 10.1124/pr.115.011239. Pharmacol Rev. 2017. PMID: 28034912 Free PMC article. Review.
-
Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus.Oncotarget. 2017 Jul 22;8(35):58872-58886. doi: 10.18632/oncotarget.19438. eCollection 2017 Aug 29. Oncotarget. 2017. PMID: 28938604 Free PMC article.
-
p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase.Mol Cancer Res. 2010 Aug;8(8):1126-41. doi: 10.1158/1541-7786.MCR-10-0174. Epub 2010 Jul 20. Mol Cancer Res. 2010. PMID: 20647331 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials